ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia.

ELN-DAVID issues key laboratory and clinical guidelines for FLT3-ITD MRD testing in AML patients in remission, supporting its role in current care standards.

• Why it matters: Accurate detection of FLT3-ITD MRD is crucial for guiding treatment decisions and improving outcomes in AML, yet standardized testing practices are needed to ensure consistency and reliability.
• What they did: The recommendations were developed through a comprehensive review of laboratory and clinical practices, aligning with the latest guidelines and emphasizing best methodologies for NGS-based FLT3-ITD MRD detection.
• The result: Implementing these guidelines will enhance the accuracy and comparability of MRD testing, ultimately aiding clinicians in risk stratification and personalized management of AML patients.